Cargando…

In vivo targeting of miR‐223 in experimental eosinophilic oesophagitis

OBJECTIVES: Eosinophilic oesophagitis (EoE) is characterised by oesophageal inflammation, fibrosis and dysfunction. Micro (mi)‐RNAs interfere with pro‐inflammatory and pro‐fibrotic transcriptional programs, and miR‐223 was upregulated in oesophageal mucosal biopsy specimens from EoE patients. The th...

Descripción completa

Detalles Bibliográficos
Autores principales: Collison, Adam M, Sokulsky, Leon A, Nightingale, Scott, Percival, Elizabeth, LeFevre, Anna, Meredith, Joseph, Krauss, Sybille, Foster, Paul S, Mattes, Joerg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683276/
https://www.ncbi.nlm.nih.gov/pubmed/33282292
http://dx.doi.org/10.1002/cti2.1210
_version_ 1783612846071873536
author Collison, Adam M
Sokulsky, Leon A
Nightingale, Scott
Percival, Elizabeth
LeFevre, Anna
Meredith, Joseph
Krauss, Sybille
Foster, Paul S
Mattes, Joerg
author_facet Collison, Adam M
Sokulsky, Leon A
Nightingale, Scott
Percival, Elizabeth
LeFevre, Anna
Meredith, Joseph
Krauss, Sybille
Foster, Paul S
Mattes, Joerg
author_sort Collison, Adam M
collection PubMed
description OBJECTIVES: Eosinophilic oesophagitis (EoE) is characterised by oesophageal inflammation, fibrosis and dysfunction. Micro (mi)‐RNAs interfere with pro‐inflammatory and pro‐fibrotic transcriptional programs, and miR‐223 was upregulated in oesophageal mucosal biopsy specimens from EoE patients. The therapeutic potential of modulating miR‐223 expression in vivo has not been determined. We aimed to elucidate the relevance of oesophageal miR‐223 expression in an in vivo model of EoE by inhibiting miR‐223 tissue expression. METHODS: The expression of miR‐223 and the validated miR‐223 target insulin‐like growth factor receptor 1 (IGF1R) protein was determined in our paediatric cohort of EoE patients. A murine model of Aspergillus fumigatus‐induced EoE was employed, and oesophagi were assessed for miR‐233, IGF1R, T lymphocyte type 2 (T2) cytokine expression and eosinophil infiltration. Mice were treated with antagomirs targeting miR‐223 or resveratrol targeting its upstream regulator Midline‐1(MID‐1). RESULTS: There was an inverse relationship between an increased expression of miR‐223 and a decreased IGF1R protein concentration in biopsy specimens from EoE patients. TNF‐related apoptosis‐inducing ligand deficiency, MID‐1 inhibition and resveratrol treatment suppressed miR‐223 expression. Furthermore, inhibition of miR‐223 and treatment with resveratrol in the oesophagus resulted in an amelioration of EoE hallmark features including eosinophilic infiltration, oesophageal circumference and a reduction in T2 cytokine expression. CONCLUSION: miR‐223 has a key role in the perpetuation of EoE hallmark features downstream of TNF‐related apoptosis‐inducing ligand and MID‐1 in an experimental model. These studies highlight a potentially critical role of miRNA function in EoE aetiology. miR‐223 expression in the oesophagus may be therapeutically modulated by resveratrol, providing a potential new therapeutic option to be explored in EoE patients for this increasingly prevalent condition.
format Online
Article
Text
id pubmed-7683276
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76832762020-12-03 In vivo targeting of miR‐223 in experimental eosinophilic oesophagitis Collison, Adam M Sokulsky, Leon A Nightingale, Scott Percival, Elizabeth LeFevre, Anna Meredith, Joseph Krauss, Sybille Foster, Paul S Mattes, Joerg Clin Transl Immunology Original Articles OBJECTIVES: Eosinophilic oesophagitis (EoE) is characterised by oesophageal inflammation, fibrosis and dysfunction. Micro (mi)‐RNAs interfere with pro‐inflammatory and pro‐fibrotic transcriptional programs, and miR‐223 was upregulated in oesophageal mucosal biopsy specimens from EoE patients. The therapeutic potential of modulating miR‐223 expression in vivo has not been determined. We aimed to elucidate the relevance of oesophageal miR‐223 expression in an in vivo model of EoE by inhibiting miR‐223 tissue expression. METHODS: The expression of miR‐223 and the validated miR‐223 target insulin‐like growth factor receptor 1 (IGF1R) protein was determined in our paediatric cohort of EoE patients. A murine model of Aspergillus fumigatus‐induced EoE was employed, and oesophagi were assessed for miR‐233, IGF1R, T lymphocyte type 2 (T2) cytokine expression and eosinophil infiltration. Mice were treated with antagomirs targeting miR‐223 or resveratrol targeting its upstream regulator Midline‐1(MID‐1). RESULTS: There was an inverse relationship between an increased expression of miR‐223 and a decreased IGF1R protein concentration in biopsy specimens from EoE patients. TNF‐related apoptosis‐inducing ligand deficiency, MID‐1 inhibition and resveratrol treatment suppressed miR‐223 expression. Furthermore, inhibition of miR‐223 and treatment with resveratrol in the oesophagus resulted in an amelioration of EoE hallmark features including eosinophilic infiltration, oesophageal circumference and a reduction in T2 cytokine expression. CONCLUSION: miR‐223 has a key role in the perpetuation of EoE hallmark features downstream of TNF‐related apoptosis‐inducing ligand and MID‐1 in an experimental model. These studies highlight a potentially critical role of miRNA function in EoE aetiology. miR‐223 expression in the oesophagus may be therapeutically modulated by resveratrol, providing a potential new therapeutic option to be explored in EoE patients for this increasingly prevalent condition. John Wiley and Sons Inc. 2020-11-23 /pmc/articles/PMC7683276/ /pubmed/33282292 http://dx.doi.org/10.1002/cti2.1210 Text en © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Collison, Adam M
Sokulsky, Leon A
Nightingale, Scott
Percival, Elizabeth
LeFevre, Anna
Meredith, Joseph
Krauss, Sybille
Foster, Paul S
Mattes, Joerg
In vivo targeting of miR‐223 in experimental eosinophilic oesophagitis
title In vivo targeting of miR‐223 in experimental eosinophilic oesophagitis
title_full In vivo targeting of miR‐223 in experimental eosinophilic oesophagitis
title_fullStr In vivo targeting of miR‐223 in experimental eosinophilic oesophagitis
title_full_unstemmed In vivo targeting of miR‐223 in experimental eosinophilic oesophagitis
title_short In vivo targeting of miR‐223 in experimental eosinophilic oesophagitis
title_sort in vivo targeting of mir‐223 in experimental eosinophilic oesophagitis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683276/
https://www.ncbi.nlm.nih.gov/pubmed/33282292
http://dx.doi.org/10.1002/cti2.1210
work_keys_str_mv AT collisonadamm invivotargetingofmir223inexperimentaleosinophilicoesophagitis
AT sokulskyleona invivotargetingofmir223inexperimentaleosinophilicoesophagitis
AT nightingalescott invivotargetingofmir223inexperimentaleosinophilicoesophagitis
AT percivalelizabeth invivotargetingofmir223inexperimentaleosinophilicoesophagitis
AT lefevreanna invivotargetingofmir223inexperimentaleosinophilicoesophagitis
AT meredithjoseph invivotargetingofmir223inexperimentaleosinophilicoesophagitis
AT krausssybille invivotargetingofmir223inexperimentaleosinophilicoesophagitis
AT fosterpauls invivotargetingofmir223inexperimentaleosinophilicoesophagitis
AT mattesjoerg invivotargetingofmir223inexperimentaleosinophilicoesophagitis